Abstract
Most of the antihypertensive drugs have a liability for adverse effects in asthma. Since there are few available data on the effect of ketanserin, a new antihypertensive drug which is a type-2 serotonin receptor antagonist, on human respiratory function, we have tested whether this drug can modify bronchial hyperresponsiveness to methacholine in asthmatic patients. The protective effect of intravenous ketanserin (0.14 mg/kg) was small, but significant.
Publication types
-
Clinical Trial
-
Controlled Clinical Trial
-
Randomized Controlled Trial
MeSH terms
-
Adult
-
Asthma / drug therapy*
-
Asthma / physiopathology
-
Bronchi / drug effects*
-
Bronchi / physiopathology
-
Bronchial Provocation Tests / methods
-
Child
-
Dose-Response Relationship, Immunologic
-
Female
-
Forced Expiratory Volume
-
Humans
-
Ketanserin / pharmacology*
-
Male
-
Methacholine Chloride
-
Methacholine Compounds / administration & dosage
-
Methacholine Compounds / antagonists & inhibitors*
-
Methacholine Compounds / immunology
-
Serotonin Antagonists / pharmacology
Substances
-
Methacholine Compounds
-
Serotonin Antagonists
-
Methacholine Chloride
-
Ketanserin